Literature DB >> 22846785

The species specificity of immunity generated by live whole organism immunisation with erythrocytic and pre-erythrocytic stages of rodent malaria parasites and implications for vaccine development.

Megumi Inoue1, Jianxia Tang, Mana Miyakoda, Osamu Kaneko, Katsuyuki Yui, Richard Culleton.   

Abstract

A promising strategy for the development of a malaria vaccine involves the use of attenuated whole parasites, as these present a greater repertoire of antigens to the immune system than subunit vaccines. The complexity of the malaria parasite's life cycle offers multiple stages on which to base an attenuated whole organism vaccine. An important consideration in the design and employment of such vaccines is the diversity of the parasites that are infective to humans. The most valuable vaccine would be one that was effective against multiple species/strains of malaria parasite. Here we compare the species specificity of pre-erythrocytic and erythrocytic whole organism vaccination using live parasites with anti-malarial drug attenuation. The cross-stage protection afforded by each vaccination strategy, and the possibility that immunity against one stage may be abrogated by exposure to other stages of both homologous and heterologous parasites was also assessed. The rodent malaria parasites Plasmodium yoelii yoelii and Plasmodium vinckei lentum are to address these questions, as they offer the widest possible genetic distance between sub-species of malaria parasites infectious to rodents. It was found that both erythrocytic and pre-erythrocytic stage immunity generated by live, attenuated parasite vaccination have species-specific components, with pre-erythrocytic stage immunity offering a much broader pan-species protection. We show that the protection achieved following sporozoite inoculation with concurrent mefloquine treatment is almost entirely dependent of CD8(+) T-cells. Evidence is presented for cross-stage protection between erythrocytic and pre-erythrocytic stage vaccination. Finally, it is shown that, with these species, an erythrocytic stage infection of either a homologous or heterologous species following immunisation with pre-erythrocytic stages does not abrogate this immunity. This is the first direct comparison of the specificity and efficacy of erythrocytic and pre-erythrocytic stage whole organism vaccination strategies utilising the same parasite species pair.
Copyright © 2012 Australian Society for Parasitology Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22846785     DOI: 10.1016/j.ijpara.2012.07.001

Source DB:  PubMed          Journal:  Int J Parasitol        ISSN: 0020-7519            Impact factor:   3.981


  12 in total

Review 1.  Chemical Attenuation in the Development of a Whole-Organism Malaria Vaccine.

Authors:  Amber I Raja; Danielle I Stanisic; Michael F Good
Journal:  Infect Immun       Date:  2017-06-20       Impact factor: 3.441

2.  Within-host competition does not select for virulence in malaria parasites; studies with Plasmodium yoelii.

Authors:  Hussein M Abkallo; Julie-Anne Tangena; Jianxia Tang; Nobuyuki Kobayashi; Megumi Inoue; Augustin Zoungrana; Nick Colegrave; Richard Culleton
Journal:  PLoS Pathog       Date:  2015-02-06       Impact factor: 6.823

3.  Species-specific immunity induced by infection with Entamoeba histolytica and Entamoeba moshkovskii in mice.

Authors:  Chikako Shimokawa; Richard Culleton; Takashi Imai; Kazutomo Suzue; Makoto Hirai; Tomoyo Taniguchi; Seiki Kobayashi; Hajime Hisaeda; Shinjiro Hamano
Journal:  PLoS One       Date:  2013-11-29       Impact factor: 3.240

4.  Studying the effect of chloroquine on sporozoite-induced protection and immune responses in Plasmodium berghei malaria.

Authors:  Else M Bijker; Krystelle Nganou-Makamdop; Geert-Jan van Gemert; Fidel Zavala; Ian Cockburn; Robert W Sauerwein
Journal:  Malar J       Date:  2015-03-26       Impact factor: 2.979

5.  Blood-stage immunity to Plasmodium chabaudi malaria following chemoprophylaxis and sporozoite immunization.

Authors:  Wiebke Nahrendorf; Philip J Spence; Irene Tumwine; Prisca Lévy; William Jarra; Robert W Sauerwein; Jean Langhorne
Journal:  Elife       Date:  2015-02-25       Impact factor: 8.140

Review 6.  Designing malaria vaccines to circumvent antigen variability.

Authors:  Amed Ouattara; Alyssa E Barry; Sheetij Dutta; Edmond J Remarque; James G Beeson; Christopher V Plowe
Journal:  Vaccine       Date:  2015-11-01       Impact factor: 3.641

7.  Rapid identification of genes controlling virulence and immunity in malaria parasites.

Authors:  Hussein M Abkallo; Axel Martinelli; Megumi Inoue; Abhinay Ramaprasad; Phonepadith Xangsayarath; Jesse Gitaka; Jianxia Tang; Kazuhide Yahata; Augustin Zoungrana; Hayato Mitaka; Arita Acharjee; Partha P Datta; Paul Hunt; Richard Carter; Osamu Kaneko; Ville Mustonen; Christopher J R Illingworth; Arnab Pain; Richard Culleton
Journal:  PLoS Pathog       Date:  2017-07-12       Impact factor: 6.823

8.  The Toll-Like Receptor 2 agonist PEG-Pam2Cys as an immunochemoprophylactic and immunochemotherapeutic against the liver and transmission stages of malaria parasites.

Authors:  Medard Ernest; Carol Hunja; Yuka Arakura; Yohei Haraga; Hussein M Abkallo; Weiguang Zeng; David C Jackson; Brendon Chua; Richard Culleton
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2018-10-23       Impact factor: 4.077

9.  Controlled Infection Immunization Using Delayed Death Drug Treatment Elicits Protective Immune Responses to Blood-Stage Malaria Parasites.

Authors:  Leanne M Low; Aloysious Ssemaganda; Xue Q Liu; Mei-Fong Ho; Victoria Ozberk; James Fink; Lana Sundac; Kylie Alcorn; Amy Morrison; Kevin O'Callaghan; John Gerrard; Danielle I Stanisic; Michael F Good
Journal:  Infect Immun       Date:  2018-12-19       Impact factor: 3.441

10.  Schistosoma mansoni infection suppresses the growth of Plasmodium yoelii parasites in the liver and reduces gametocyte infectivity to mosquitoes.

Authors:  Taeko Moriyasu; Risa Nakamura; Sharmina Deloer; Masachika Senba; Masato Kubo; Megumi Inoue; Richard Culleton; Shinjiro Hamano
Journal:  PLoS Negl Trop Dis       Date:  2018-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.